Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines
复制标题
DOI：
10.1007/s00520-014-2372-3
复制
发表时间：
2015-01-01
影响因子：
3.1
通讯作者：
Keefe, Dorothy M. K.
中科院分区：
文献类型：
--
作者：
Yu, Shiying;Burke, Thomas A.;Keefe, Dorothy M. K.
本文报告了六个亚太国家癌症高度或中度致吐化疗（HEC 或 MEC）后预防化疗引起的恶心和呕吐 (CINV) 的处方模式。 在一项前瞻性非干预研究中，澳大利亚、中国、印度、新加坡、韩国和台湾的 31 个中心记录了成人患者单日 HEC 或 MEC 后急性期（前 24 小时）和延迟期（第 2-5 天）CINV 预防的详细信息。有关 CINV 预防药物的更多信息是从 6 天患者日记中收集的。主要止吐治疗被定义为皮质类固醇、5-羟色胺-3受体拮抗剂 (5HT3-RAs) 和神经激肽-1受体拮抗剂 (NK1-RAs)。第 1 周期中可评估的患者人数为 648 名（318 [49%] HEC 和 330 [51%] MEC），平均 (SD) 年龄为 56 (12) 岁，其中 58% 为女性。对于 HEC 后的急性期，总体而言（和国家范围），96% (91-100%) 的患者接受了 5HT3-RA，87% (70-100%) 的患者接受了皮质类固醇，43% (0-91%) 的患者接受了 NK1-RA。 HEC 延迟期的 CINV 预防变化更大：包括 22 % (7-65 %) 5HT3-RA、52 % (12-93 %) 皮质类固醇和 46 % (0-88 %) NK1-RA。对于 MEC 急性期，97% (87-100%) 的患者接受 5HT3-RA 和 86% (73-97%) 皮质类固醇治疗。对于 MEC 延迟期，201 名患者 (61%) 接受了主要止吐药，包括 5HT3-RA (41%)、皮质类固醇 (37%) 和/或 NK1-RA (4%)。所有国家均一致开出 5HT3-RA，而其他止吐疗法的处方各不相同，并且用于 CINV 预防的皮质类固醇处方不足，尤其是在延迟期。
This paper reports prescribing patterns for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries.In a prospective noninterventional study, 31 sites in Australia, China, India, Singapore, South Korea, and Taiwan recorded details of CINV prophylaxis for the acute phase (first 24 h) and delayed phase (days 2-5) after single-day HEC or MEC for adult patients. Additional information on CINV prophylactic medications was collected from 6-day patient diaries. Primary antiemetic therapies were defined as corticosteroids, the 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), and neurokinin-1 receptor antagonists (NK1-RAs).Evaluable patients in cycle 1 numbered 648 (318 [49 %] HEC and 330 [51 %] MEC) of mean (SD) age of 56 (12) years, including 58 % women. For the acute phase after HEC, overall (and country range), 96 % (91-100 %) of patients received a 5HT3-RA, 87 % (70-100 %) a corticosteroid, and 43 % (0-91 %) an NK1-RA. CINV prophylaxis for the HEC delayed phase was more variable: including 22 % (7-65 %) 5HT3-RA, 52 % (12-93 %) corticosteroid, and 46 % (0-88 %) NK1-RA. For the MEC acute phase, 97 % (87-100 %) of patients received 5HT3-RA and 86 % (73-97 %) a corticosteroid. For the MEC delayed phase, 201 patients (61 %) received a primary antiemetic, including 5HT3-RA (41 %), corticosteroid (37 %), and/or NK1-RA (4 %).The 5HT3-RAs were prescribed consistently in all countries, while prescribing of other antiemetic therapies was variable, and corticosteroids were under-prescribed for CINV prophylaxis, particularly in the delayed phase.